{
    "root": "24fcd7b4-da33-4e24-bf31-3f1b5f51d800",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ELAPRASE",
    "value": "20250225",
    "ingredients": [
        {
            "name": "idursulfase",
            "code": "5W8JGG2651"
        },
        {
            "name": "sodium chloride",
            "code": "451W47IQ8X"
        },
        {
            "name": "sodium phosphate, monobasic, monohydrate",
            "code": "593YOG76RN"
        },
        {
            "name": "sodium phosphate, dibasic, heptahydrate",
            "code": "70WT22SF4B"
        },
        {
            "name": "polysorbate 20",
            "code": "7T1F30V5YH"
        }
    ],
    "indications": "elaprase indicated patients hunter syndrome ( mucopolysaccharidosis ii , mps ii ) . elaprase shown improve walking capacity patients 5 years older . patients 16 months 5 years age , data available demonstrate improvement disease-related symptoms long term outcome ; however , treatment elaprase reduced spleen volume similarly adults children 5 years age older . safety efficacy elaprase established pediatric patients less 16 months age [ ( 8.4 ) ] .",
    "contraindications": "recommended 0.5 mg per kg body weight administered every week intravenous infusion ( 2 ) .",
    "warningsAndPrecautions": "elaprase supplied sterile injection 5 ml type glass vial . vials closed butyl rubber stopper fluororesin coating aluminum overseal blue flip-off plastic cap . carton contains single vial ndc 54092-700-01",
    "adverseReactions": "none .",
    "indications_original": "ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older.\n                  In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older.\n                  The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age [see Use in Specific Populations (8.4)].",
    "contraindications_original": "The recommended dosage is 0.5 mg per kg of body weight administered once every week as an intravenous infusion ( 2 ).",
    "warningsAndPrecautions_original": "ELAPRASE is supplied as a sterile injection in a 5 mL Type I glass vial. The vials are closed with a butyl rubber stopper with fluororesin coating and an aluminum overseal with a blue flip-off plastic cap.\n                  Each carton contains a single vial \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 54092-700-01",
    "adverseReactions_original": "None."
}